• Journals Master List
  • DOAJ
  • 数据库logo
  • EuroPub
CHENG Li, MIN Yong-long, WAN Sheng, HE Da, CHEN Fang, ZHANG Yan-min, XIONG Fei. Comparison of calcium-phosphorus metabolism between peritoneal dialysis and hemodialysis patients and analysis of influencing factors[J]. Journal of Clinical Nephrology, 2020, 20(11): 886-890. DOI: 10.3969/j.issn.1671-2390.2020.11.007
Citation: CHENG Li, MIN Yong-long, WAN Sheng, HE Da, CHEN Fang, ZHANG Yan-min, XIONG Fei. Comparison of calcium-phosphorus metabolism between peritoneal dialysis and hemodialysis patients and analysis of influencing factors[J]. Journal of Clinical Nephrology, 2020, 20(11): 886-890. DOI: 10.3969/j.issn.1671-2390.2020.11.007

Comparison of calcium-phosphorus metabolism between peritoneal dialysis and hemodialysis patients and analysis of influencing factors

More Information
  • Received Date: November 23, 2019
  • Available Online: May 11, 2023
  • Published Date: November 27, 2020
  • Objective To compare the effects of peritoneal dialysis(PD)and hemodialysis(HD)on calcium-phosphorous metabolism in uremic patients,and to analyze the related influencing factors so as to provide basis and improvement measures for the clinical treatment.Methods The clinical data of PD and HD patients undergoing maintenance PD and HD in our hospital from October 1st,2018 to October 1st,2019 were collected and analyzed retrospectively.The serum calcium,phosphorus and intact parathyroid hormone were collected and compared between the patients with PD and HD at 0,3,6 and 12 months of dialysis.Multivariate linear regression was used to analyze the related influencing factors of calcium-phosphorus metabolism abnormality.Results (1)The levels of serum phosphorus at 3(t=-4.044,P<0.001),6(t=-5.886,P<0.001)and 12(t=-7.808,P<0.001)months of dialysis in the HD group were all higher than those in the PD group.The levels of serum calcium at 6(t=6.521,P<0.001)and 12(t=6.841,P<0.001)moths of dialysis were lower than those in the PD group,and the level of calcium-phosphorus product at 12 months(t=-2.080,P=0.038)was higher than that in the PD group.(2).After 12 months of dialysis,the compliance rates of serum phosphorus(χ2=4.329,P=0.037),serum calcium(χ2=5.587,P=0.018)and calcium-phosphorus product(χ2=5.750,P=0.016)in the PD group were significantly higher than those in the HD group.(3)The multivariate linear regression analysis of the factors that may influence the calcium-phosphorous metabolism in dialysis patients showed that the dialysis modality(B=-0.287,P=0.005),age(B=-0.010,P=0.005),dialysis duration(B=-0.010,P=0.027),and sodium(Na)(B=-0.026,P=0.033)were the independent influencing factors of the level of serum phosphorus,with negative correlation.Conclusions Compared with HD,the levels of serum phosphorus and calcium can be controlled better by PD.Low age,low dialysis age and low sodium were independent influencing factors of increase blood phosphorus level.
  • [1]
    Liyanage T,Ninomiya T,Jha V,et al.Worldwide access to treatment for end-stage kidney disease:a systematic review[J]. Lancet,2015,385(9981):1975-1982.DOI: 10.1016/s0140-6736(14)61601-9.
    [2]
    Saran R,Li Y,Robinson B,et al.USrenal data system 2014 annual data report:epidemiology of kidney disease in the United States[J]. Am J Kidney Dis,2015,66(1 suppl 1):Svii,S1-Svii,S305.DOI: 10.1053/j.ajkd.2015.05.001.
    [3]
    Xue J,Li H,Zhou Q,et al.Comparison of peritoneal dialysis with hemodialysis on survival of diabetic patients with end-stage kidney disease:a meta-analysis of cohort studies[J]. Ren Fail,2019,41(1):521-531.DOI: 10.1080/0886022x.2019.1625788.
    [4]
    Waziri B,Duarte R,Naicker S.Chronic kidney disease-mineral and bone disorder(CKD-MBD):current perspectives[J]. Int J Nephrol Renovasc Dis,2019,12:263-276.DOI: 10.2147/ijnrd.s191156.
    [5]
    Wang M,Obi Y,Streja E,et al.Association of parameters of mineral bone disorder with mortality in patients on hemodialysis according to level of residual kidney function[J]. Clin J Am Soc Nephrol,2017,12(7):1118-1127.DOI: 10.2215/cjn.11931116.
    [6]
    中国医师协会肾脏病医师分会血液透析充分性协作组.中国血液透析充分性临床实践指南[J]. 中华医学杂志,2015,95(34):2748-2753.DOI: 10.3760/cma.j.issn.0376-2491.2015.34.004.
    [7]
    Isakova T,Nickolas TL,Denburg M,et al.KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J]. Am J Kidney Dis,2017,70(6):737-751.DOI: 10.1053/j.ajkd.2017.07.019.
    [8]
    Fang X,Kang M,Chen D,et al.Comparison of mortality between peritoneal dialysis and hemodialysis in polycystic kidney disease[J]. Ren Fail,2019,41(1):14-15.DOI: 10.1080/0886022x.2018.1487867.
    [9]
    Banshodani M,Kawanishi H,Moriishi M,et al.Association betweendialysis modality and cardiovascular diseases:a comparison between peritoneal dialysis and hemodialysis[J]. Blood Purif,2020,49(3):302-309.DOI: 10.1159/000504040.
    [10]
    Lamina C,Kronenberg F,Stenvinkel P,et al.Association of changes in bone mineral parameters with mortality in haemodialysis patients:insights from the ARO cohort[J]. Nephrol Dial Transplant,2020,35(3):478-487.DOI: 10.1093/ndt/gfz060.
    [11]
    由波.腹膜透析和血液透析对尿毒症患者钙磷代谢影响的临床研究[J]. 中国实用医药,2017,12(8):76-78.DOI: 10.14163/j.cnki.11-5547/r.2017.08.033.
    [12]
    肖艳美,张文贤,董小伟,等.腹膜透析和血液透析对尿毒症患者钙磷代谢影响的临床研究[J]. 中国医药指南,2017,15(32):181.
    [13]
    Noordzij M,Korevaar JC,Bos WJ,et al.Mineral metabolism and cardiovascular morbidity and mortality risk:peritoneal dialysis patients compared with haemodialysis patients[J]. Nephrol Dial Transplant,2006,21(9):2513-2520.DOI: 10.1093/ndt/gfl257.
    [14]
    黄力,关洁仪,陈玉平.血液透析与腹膜透析对尿毒症患者在钙、磷代谢中的影响探析[J]. 中国医学创新,2016,13(9):40-42.DOI: 10.3969/j.issn.1674-4985.2016.09.011.
    [15]
    Palmer SC,Hayen A,Macaskill P,et al.Serum levels of phosphorus,parathyroid hormone,and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease:a systematic review and meta-analysis[J]. JAMA,2011,305(11):1119-1127.DOI: 10.1001/jama.2011.308.
    [16]
    Kong X,Zhang L,Zhang L,et al.Mineral and bone disorder in Chinese dialysis patients:a multicenter study[J]. BMC Nephrol,2012,13:116.DOI: 10.1186/1471-2369-13-116.
    [17]
    Dang ZH,Tang C,Li GL,et al.Mineral and bone disorder in hemodialysis patients in the Tibetan Plateau:a multicenter cross-sectional study[J]. Ren Fail,2019,41(1):636-643.DOI: 10.1080/0886022x.2019.1635892.
    [18]
    Evenepoel P,Meijers BK,Bammens B,et al.Phosphorus metabolism in peritoneal dialysis-and haemodialysis-treated patients[J]. Nephrol Dial Transplant,2016,31(9):1508-1514.DOI: 10.1093/ndt/gfv414.
    [19]
    林明增,陈霄峰,范佳妮,等.腹膜透析和血液透析对尿毒症患者钙磷代谢影响的临床研究[J]. 中国血液净化,2013,12(9):487-490.DOI: 10.3969/j.issn.1671-4091.2013.09.006.
    [20]
    Kiss I,Kiss Z,Ambrus C,et al.Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary:results from a nationwide clinical audit[J]. BMC Nephrol,2013,14:155.DOI: 10.1186/1471-2369-14-155.
    [21]
    Rroji M,Seferi S,Cafka M,et al.Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?[J]. Int Urol Nephrol,2014,46(1):175-182.DOI: 10.1007/s11255-013-0438-7.
    [22]
    van der Wijst J,TutakhelOAZ,Bos C,et al.Effects of a high-sodium/low-potassium diet on renal calcium,magnesium,and phosphate handling[J]. Am J Physiol Renal Physiol,2018,315(1):F110-F122.DOI: 10.1152/ajprenal.00379.2017.
    [23]
    Vallon V,Schroth J,Lang F,et al.Expression and phosphorylation of the Na+-Cl-cotransporter NCC in vivo is regulated by dietary salt,potassium,and SGK1[J]. Am J Physiol Renal Physiol,2009,297(3):F704-F712.DOI: 10.1152/ajprenal.00030.2009.

Catalog

    Article views (309) PDF downloads (396) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return